Abstract
The eye is the organ in charge of vision and, given its properties, has become an excellent organ to test genetic therapies, including antisense oligonucleotide (AON) technology. In fact, the first AON receiving FDA and EMA approval was meant to treat an eye condition. Currently, dozens of clinical trials are being conducted for a variety of subtypes of inherited retinal disease. Although most of them are based on gene augmentation therapies, a phase 3 and two phase 1/2 clinical trials using AONs are ongoing. Since the retina is a layered structure of nondividing cells, obtaining human retinal tissue and expanding it in the lab is not possible, unless induced pluripotent stem cell technology is used. Mouse models have helped to elucidate the function of many genes, and the retinal structure is quite similar to that of humans. Thus, drug delivery to the mouse eye can provide valuable information for further optimization of therapies. In this chapter, the protocol for intravitreal injections of AONs is described in detail.
Full text of this article can be found in Bookshelf.
References
- Kolb H (2003) How the retina works. Am Sci 91(1):28–35. citeulike-article-id:1560678
- Vazquez-Dominguez I, Garanto A, Collin RWJ (2019) Molecular therapies for inherited retinal diseases-current standing, opportunities and challenges. Genes (Basel) 10(9):654. https://doi.org/10.3390/genes10090654 doi: 10.3390/genes10090654. [DOI] [PMC free article] [PubMed]
- Keeler AM, Flotte TR (2019) Recombinant adeno-associated virus gene therapy in light of Luxturna (and Zolgensma and Glybera): where are we, and how did we get here? Annu Rev Virol 6(1):601–621. https://doi.org/10.1146/annurev-virology-092818-015530 doi: 10.1146/annurev-virology-092818-015530. [DOI] [PMC free article] [PubMed]
- Hammond SM, Wood MJ (2011) Genetic therapies for RNA mis-splicing diseases. Trends Genet 27(5):196–205. https://doi.org/10.1016/j.tig.2011.02.004 doi: 10.1016/j.tig.2011.02.004. [DOI] [PubMed]
- Cideciyan AV, Jacobson SG, Ho A, Drack A, Pfeifer W, Charng J, Taiel M, Schwartz M, Biasutto P, de Wit W, Cheetham ME, Adamson P, Rodman D, Nerinckx F, De Zaeytijd J, van Cauwenbergh C, Leroy BP, Russel S (2018) Intravitreal antisense oligonucleotide therapy (QR-110) for the Treatment of Leber Congenital Amaurosis due to Photoreceptor Cilium Defect in Subjects with the CEP290 p.Cys998X Mutation. Paper presented at the RD2018 XVIIIth international symposium on retinal degeneration, Killarney, Ireland
- Garanto A, van Beersum SE, Peters TA, Roepman R, Cremers FP, Collin RW (2013) Unexpected CEP290 mRNA splicing in a humanized knock-in mouse model for Leber congenital amaurosis. PLoS One 8(11):e79369. https://doi.org/10.1371/journal.pone.0079369 doi: 10.1371/journal.pone.0079369. [DOI] [PMC free article] [PubMed]
- Collin RW, den Hollander AI, van der Velde-Visser SD, Bennicelli J, Bennett J, Cremers FP (2012) Antisense oligonucleotide (AON)-based therapy for Leber congenital amaurosis caused by a frequent mutation in CEP290. Mol Ther Nucleic Acids 1:e14. https://doi.org/10.1038/mtna.2012.3 doi: 10.1038/mtna.2012.3. [DOI] [PMC free article] [PubMed]
- Garanto A, Chung DC, Duijkers L, Corral-Serrano JC, Messchaert M, Xiao R, Bennett J, Vandenberghe LH, Collin RW (2016) In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by antisense oligonucleotide delivery. Hum Mol Genet 25(12):2552–2563. https://doi.org/10.1093/hmg/ddw118 doi: 10.1093/hmg/ddw118. [DOI] [PMC free article] [PubMed]
- Surace EM, Auricchio A (2008) Versatility of AAV vectors for retinal gene transfer. Vis Res 48(3):353–359. https://doi.org/10.1016/j.visres.2007.07.027 doi: 10.1016/j.visres.2007.07.027. [DOI] [PubMed]
- Toulis V, Garanto A, Marfany G (2016) Combining zebrafish and mouse models to test the function of deubiquitinating enzyme (Dubs) genes in development: role of USP45 in the retina. Methods Mol Biol 1449:85–101. https://doi.org/10.1007/978-1-4939-3756-1_3 doi: 10.1007/978-1-4939-3756-1_3. [DOI] [PubMed]